Scancell, the Nottingham based cancer vaccine developer, announced in an update on the SCIB1 trial that the second cohort of three patients has been evaluated by the Cohort Review Committee, which approved further escalation of the dose to 4mg (from 2mg) and recruitment of the final group of patients as planned. The Phase 2 study is expected to start in late 2011/early 2012 on schedule.

The company also announced that Katherine Cornish-Bowden has been appointed as a non executive director. She was the managing director and head of Morgan Stanley Investment Management's Global Core Equity Team between 2002 and 2004, and has been a director of Investec Structured Products Calculus VCT Plc since February 2011.

Finally, Helium Special Situations Fund Limited increased its stake in the company to 8.16%.

The SCLP share price has decreased by 39% over the last six months.

Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here